When something's off, but no routine panel explains it.

Peptides are short chains of amino acids that signal a specific process in the body, like hormone release or a metabolic pathway, rather than replacing something outright.

Each compound works differently. Sermorelin binds a receptor on the pituitary gland to trigger GH release; NAD+ participates directly in cellular energy production; B12-MIC supports methylation and fat metabolism.

No. A US-licensed clinician reviews your labs and health history first. If a specific compound may be appropriate for your goals, they'll recommend it. If not, they'll explain why.

That depends on your labs and goals. Sleep and recovery concerns are often discussed alongside Sermorelin, general energy and perceived mental clarity alongside NAD+, and suspected B12 deficiency alongside B12-MIC. Your clinician makes the final call.

Patients who are pregnant or breastfeeding, have an active malignancy, or have a pituitary condition (for Sermorelin specifically) are generally not candidates. Diabetes, thyroid, kidney, or liver disease, and current medications, are also reviewed before prescribing.

No, not for these uses. Sermorelin's original branded version had a narrow pediatric approval that was discontinued in 2008. B12 is FDA-approved for treating diagnosed deficiency, but the B12-MIC combination is off-label. NAD+ is not FDA-approved for any indication.

Testosterone replacement therapy (TRT) directly replaces a clinically low hormone. Sermorelin instead signals the pituitary gland to release more of your own growth hormone, rather than supplying a hormone directly.

NAD+ acts inside cells to support energy production and metabolic pathways. Sermorelin acts on the pituitary gland to influence hormone signaling. They target different systems and are typically considered for different goals.

B12-MIC is closer to a vitamin/lipotropic injection than the other two compounds. NAD+ and Sermorelin work through cellular and hormonal signaling pathways rather than correcting a nutrient deficiency.

This depends on the compound and your clinician's plan; medication ships every 4 weeks. There's no fixed end date. Continuing, adjusting, or stopping is reviewed at quarterly monitoring visits based on your response.

Your clinician and pharmacy provide compound-specific storage instructions when your medication ships, since requirements vary (some require refrigeration).

Effects tied to ongoing signaling, like Sermorelin's influence on GH release, typically fade once you stop. This is discussed with your clinician as part of your monitoring plan.

Combining peptides happens only under clinician guidance, based on your labs and goals, not as a default bundle.

Usually not, since these are off-label, compounded, cash-pay treatments. FDA-approved uses, like B12 for a diagnosed deficiency, are more likely to have a coverage pathway elsewhere.

This varies by compound and by what you're tracking. Response varies considerably between individuals, and no established timeline applies to everyone.

Sermorelin is available to patients aged 25 and older only, under the Prometheuz clinical intake protocol, reflecting where growth hormone baselines are more established.